/ LLY


Eli Lilly & Co. Reports Third Quarter with $1.18 EPS, Downgrades Guidance
/ Earnings

Eli Lilly & Co. Reports Third Quarter with $1.18 EPS, Downgrades Guidance

Eli Lilly & Co. reported its results for the third quarter of 2024, with revenue up 20% y/y but failing to meet market expectations.

October 30, 2024
Stocks to Watch Today: Tesla, LLY, and Bank of America

Stocks to Watch Today: Tesla, LLY, and Bank of America

Eli Lilly's stock surged on news of its diabetes drug while Tesla saw a modest gain following news of reduced EU tariffs. Meanwhile, BAC declined after Berkshire Hathaway sold a significant portion of ...

August 20, 2024
Stocks to Watch Today: LLY, WBD, and AMAT

Stocks to Watch Today: LLY, WBD, and AMAT

Eli Lilly (LLY) surged on strong Q2 earnings driven by GLP-1 drug sales, while Warner Bros. Discovery (WBD) plummeted following a massive $11.2 billion impairment charge.

August 08, 2024
Eli Lilly and Company (LLY) Shines in Q2 with $11.30 B Revenue, 68% EPS Growth

Eli Lilly and Company (LLY) Shines in Q2 with $11.30 B Revenue, 68% EPS Growth

Eli Lilly and Company (NYSE: LLY) has reported a strong financial performance for the second quarter of 2024, with revenue reaching $11.30 billion.

August 08, 2024
Eli Lilly Enters the Chinese Market as Tirzepatide Gains Approval, Shares Gain

Eli Lilly Enters the Chinese Market as Tirzepatide Gains Approval, Shares Gain

Eli Lilly's weight loss drug tirzepatide has received approval from Chinese regulators, intensifying competition with Novo Nordisk.

July 19, 2024

100% FREE TRIAL: Learn how to day trade (the right way) with the #1 voted live trading room!

X